Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation

Pediatr Infect Dis J. 2012 Apr;31(4):389-91. doi: 10.1097/INF.0b013e3182401c41.

Abstract

We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to 12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacokinetics*
  • Antitubercular Agents / administration & dosage
  • Area Under Curve
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Infant
  • Male
  • Nevirapine / administration & dosage
  • Nevirapine / pharmacokinetics*
  • Plasma / chemistry
  • Rifampin / administration & dosage
  • Tuberculosis / complications*
  • Tuberculosis / drug therapy*

Substances

  • Anti-HIV Agents
  • Antitubercular Agents
  • Nevirapine
  • Rifampin